What clinicians need to know about intranasal esketamine for treatment-resistant depression?
Open Access
- 14 November 2023
- journal article
- research article
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 31 (6) , 841-845
Abstract
Objective: To review the usefulness of esketamine for treatment-resistant depression. Method: Pivotal trials of intranasal esketamine in treatment-resistant depression were synthesized as a narrative review. Results: Esketamine is postulated to act through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, but opioidergic effects may also be involved. Unlike intravenous ketamine, esketamine is given intranasally (under clinical observation), usually in addition to an oral antidepressant. Trials compared esketamine plus antidepressant versus placebo plus antidepressant. At 4 weeks, remission was 37% higher with esketamine/antidepressant than placebo/antidepressant. Speed of response and improvement in suicidality were comparable. In stable remitters on esketamine/antidepressant, 45% relapsed when esketamine was withdrawn over the following 6 months (whereas 25% relapsed on esketamine/antidepressant). Response appears less likely in patients with multiple antidepressant failures. Adverse effects include dissociation, dizziness, nausea, sedation, and headache but no psychosis. Hypertension affected 13%, especially older patients. Dose frequency is twice-weekly for 4 weeks, then weekly/fortnightly thereafter. No abuse has been reported. Unsubsidised cost may be beyond the reach of many Australians. Conclusion: Intranasal esketamine plus antidepressant has been approved by regulators as moderately effective and acceptably tolerable for treatment-resistant depression. Cost is a drawback. Use often needs to be long-term and vigilance for abuse is essential.Keywords
This publication has 18 references indexed in Scilit:
- Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant DepressionThe Journal of Clinical Psychiatry, 2020
- Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3The American Journal of Geriatric Psychiatry, 2020
- Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodentsProceedings of the National Academy of Sciences, 2020
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant DepressionJAMA Psychiatry, 2019
- Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonismMolecular Psychiatry, 2019
- Esketamine for treatment resistant depressionExpert Review of Neurotherapeutics, 2019
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)International Journal of Neuropsychopharmacology, 2019
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled StudyAmerican Journal of Psychiatry, 2019
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2018
- A typology of reviews: an analysis of 14 review types and associated methodologiesHealth Information & Libraries Journal, 2009